Reading List

The most recent articles from a list of feeds I subscribe to.

Facebook will pay TikTok and YouTube creators up to $3,000 a month to post Reels on its platform


Meta’s Creator Fast Track programme guarantees three months of pay for established creators willing to build a following on Facebook, after the company paid out a record $3 billion to creators in 2025. Facebook has a creator problem that three billion monthly users cannot solve. The platform is enormous, but the creators who drive the […]



This story continues at The Next Web

GlobalComix raises $13M, acquires INKR, and appoints new CEO to build the infrastructure for global comics distribution


The New York digital comics platform is combining its 300,000-title library with INKR’s AI localisation engine, and bringing in new leadership to execute the expansion. The problem with getting manga into the hands of readers outside Japan is not demand. Manga is the fastest-growing category in American book publishing; global interest has been building for […]



This story continues at The Next Web

Homaio raises €3.6M to bring carbon allowance investing to retail


The Paris startup opened the EU’s emissions trading market to private investors in 2024. Now it has the backing to expand into energy, electrification, and other markets shaping the industrial transition. Valentin Lautier says he got the idea for Homaio on the Eurostar. He was reading a Financial Times article about European Union Allowances, the […]



This story continues at The Next Web

Multiply raises $9.5M to build AI agents that keep B2B ad campaigns from going stale


The San Francisco startup emerges from stealth with Mayfield backing and a pitch that treats ad creative as a continuous learning loop, not a quarterly deliverable. Every B2B marketing team knows the problem. A campaign launches, the creative is fresh, the targeting feels right, and then, slowly, it starts dying. Audiences tune out. Click rates […]



This story continues at The Next Web

German biotech Kupando raises €10M more to take its innate immunity drug into the clinic


An extension to the company’s Series A brings total funding to €23 million and clears the path for the first human trial of KUP101, a dual TLR agonist targeting solid tumours and drug-resistant infections. Most immunotherapy research in oncology has concentrated on the adaptive immune system, the learned, antibody-generating machinery that checkpoint inhibitors like pembrolizumab […]



This story continues at The Next Web